Breaking News

USP Expands Support for Controlling Impurities in Medicines

New portfolio of pharmaceutical analytical impurities aims to support drug R&D and method development.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

The U.S. Pharmacopeia (USP) has launched a new portfolio of impurities materials to support pharmaceutical manufacturers efforts to accelerate and strengthen analytical R&D and process development. USP Pharmaceutical Analytical Impurities (PAIs) support impurity analysis and profiling requirements during drug development and throughout the product lifecycle.   Changes in the pharmaceutical industry, including new manufacturing processes, more complicated drug formulations and an increasing...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters